Trinity Biotech plc (TRIB)
USD 0.53
(-1.65%)
USD 0.53
(-1.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -27.04 Million USD | -39.83% |
| 2022 | -10.91 Million USD | -182.96% |
| 2021 | 13.15 Million USD | -31.15% |
| 2020 | 19.1 Million USD | 2091.06% |
| 2019 | 872 Thousand USD | -73.55% |
| 2018 | 3.29 Million USD | -39.81% |
| 2017 | 5.47 Million USD | -26.87% |
| 2016 | 7.49 Million USD | -44.3% |
| 2015 | 13.44 Million USD | -25.44% |
| 2014 | 18.03 Million USD | 0.93% |
| 2013 | 17.87 Million USD | 4.12% |
| 2012 | 17.16 Million USD | 8.76% |
| 2011 | 15.78 Million USD | 12.51% |
| 2010 | 14.02 Million USD | -0.5% |
| 2009 | 14.09 Million USD | 117.72% |
| 2008 | -79.57 Million USD | -170.92% |
| 2007 | -29.37 Million USD | -1613.24% |
| 2006 | 1.94 Million USD | -70.69% |
| 2005 | 6.62 Million USD | 15.35% |
| 2004 | 5.74 Million USD | -40.62% |
| 2003 | 9.66 Million USD | 49.71% |
| 2002 | 6.45 Million USD | 196.22% |
| 2001 | 2.18 Million USD | -66.47% |
| 2000 | 6.5 Million USD | 25.89% |
| 1999 | 5.16 Million USD | 78.12% |
| 1998 | 2.9 Million USD | 480.0% |
| 1997 | 500 Thousand USD | 171.43% |
| 1996 | -700 Thousand USD | 61.11% |
| 1995 | -1.8 Million USD | 33.33% |
| 1994 | -2.7 Million USD | 35.71% |
| 1993 | -4.2 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.68 Million USD | -31.99% |
| 2024 Q1 | -3.07 Million USD | 12.01% |
| 2023 Q1 | -3.91 Million USD | 17.96% |
| 2023 Q4 | -3.48 Million USD | 22.47% |
| 2023 Q3 | -4.5 Million USD | 69.7% |
| 2023 Q2 | -14.85 Million USD | -278.97% |
| 2023 FY | -15.26 Million USD | -39.83% |
| 2022 Q2 | -1.51 Million USD | 85.13% |
| 2022 Q4 | -4.77 Million USD | 0.44% |
| 2022 FY | -10.91 Million USD | -182.96% |
| 2022 Q1 | -10.18 Million USD | -715.45% |
| 2022 Q3 | -4.79 Million USD | -216.7% |
| 2021 Q4 | -1.24 Million USD | -145.45% |
| 2021 Q1 | 3.07 Million USD | -66.05% |
| 2021 Q3 | 2.74 Million USD | -56.28% |
| 2021 FY | 13.15 Million USD | -31.15% |
| 2021 Q2 | 6.28 Million USD | 104.22% |
| 2020 Q2 | 501 Thousand USD | -70.41% |
| 2020 FY | 19.1 Million USD | 2091.06% |
| 2020 Q3 | 9.08 Million USD | 1713.37% |
| 2020 Q1 | 1.69 Million USD | 17.24% |
| 2020 Q4 | 9.06 Million USD | -0.21% |
| 2019 FY | 872 Thousand USD | -73.55% |
| 2019 Q2 | 1.2 Million USD | -8.71% |
| 2019 Q1 | 1.32 Million USD | -31.14% |
| 2019 Q4 | 1.44 Million USD | 8.33% |
| 2019 Q3 | 1.33 Million USD | 10.62% |
| 2018 Q1 | 1.8 Million USD | 122.96% |
| 2018 Q3 | 1.23 Million USD | -28.39% |
| 2018 Q4 | 1.91 Million USD | 55.1% |
| 2018 Q2 | 1.72 Million USD | -4.43% |
| 2018 FY | 3.29 Million USD | -39.81% |
| 2017 FY | 5.47 Million USD | -26.87% |
| 2017 Q2 | 1.83 Million USD | 40.06% |
| 2017 Q3 | 1.52 Million USD | -16.59% |
| 2017 Q4 | 810 Thousand USD | -46.99% |
| 2017 Q1 | 1.3 Million USD | 120.57% |
| 2016 Q3 | 2.71 Million USD | 15.37% |
| 2016 FY | 7.49 Million USD | -44.3% |
| 2016 Q2 | 2.35 Million USD | 29.1% |
| 2016 Q1 | 1.82 Million USD | -41.71% |
| 2016 Q4 | 593 Thousand USD | -78.18% |
| 2015 Q1 | 4.33 Million USD | 0.88% |
| 2015 FY | 13.44 Million USD | -25.44% |
| 2015 Q3 | 2.97 Million USD | -1.3% |
| 2015 Q2 | 3.01 Million USD | -30.57% |
| 2015 Q4 | 3.13 Million USD | 5.39% |
| 2014 FY | 18.03 Million USD | 0.93% |
| 2014 Q1 | 4.5 Million USD | -10.42% |
| 2014 Q4 | 4.29 Million USD | -7.45% |
| 2014 Q3 | 4.64 Million USD | 1.09% |
| 2014 Q2 | 4.59 Million USD | 1.98% |
| 2013 Q4 | 5.02 Million USD | 1.72% |
| 2013 Q1 | 4.06 Million USD | -7.45% |
| 2013 FY | 17.87 Million USD | 4.12% |
| 2013 Q3 | 4.94 Million USD | 28.72% |
| 2013 Q2 | 3.84 Million USD | -5.47% |
| 2012 FY | 17.16 Million USD | 8.76% |
| 2012 Q4 | 4.38 Million USD | 0.92% |
| 2012 Q3 | 4.34 Million USD | 1.23% |
| 2012 Q2 | 4.29 Million USD | 3.97% |
| 2012 Q1 | 4.13 Million USD | 0.85% |
| 2011 Q4 | 4.09 Million USD | -0.07% |
| 2011 Q3 | 4.1 Million USD | 5.45% |
| 2011 Q1 | 3.69 Million USD | 15.77% |
| 2011 Q2 | 3.88 Million USD | 5.11% |
| 2011 FY | 15.78 Million USD | 12.51% |
| 2010 Q2 | 3.5 Million USD | -4.54% |
| 2010 Q1 | 3.67 Million USD | 5.48% |
| 2010 Q3 | 3.26 Million USD | -6.9% |
| 2010 Q4 | 3.19 Million USD | -2.2% |
| 2010 FY | 14.02 Million USD | -0.5% |
| 2009 Q1 | 3.04 Million USD | 103.55% |
| 2009 FY | 14.09 Million USD | 117.72% |
| 2009 Q2 | 3.84 Million USD | 26.27% |
| 2009 Q3 | 3.73 Million USD | -2.86% |
| 2009 Q4 | 3.48 Million USD | -6.59% |
| 2008 Q2 | 2.31 Million USD | 29.87% |
| 2008 Q3 | 2.01 Million USD | -12.93% |
| 2008 Q4 | -85.68 Million USD | -4354.27% |
| 2008 FY | -79.57 Million USD | -170.92% |
| 2008 Q1 | 1.78 Million USD | 101.03% |
| 2007 Q3 | 34.73 Million USD | 839.29% |
| 2007 Q4 | -172.98 Million USD | -598.03% |
| 2007 Q2 | 3.69 Million USD | 11.65% |
| 2007 Q1 | 3.31 Million USD | 195.45% |
| 2007 FY | -29.37 Million USD | -1613.24% |
| 2006 Q2 | -3.72 Million USD | -334.74% |
| 2006 Q1 | 1.58 Million USD | 16.11% |
| 2006 Q3 | 2.95 Million USD | 179.45% |
| 2006 Q4 | 1.12 Million USD | -62.1% |
| 2006 FY | 1.94 Million USD | -70.69% |
| 2005 Q3 | 2.14 Million USD | 28.62% |
| 2005 Q2 | 1.67 Million USD | 16.13% |
| 2005 Q1 | 1.43 Million USD | -17.69% |
| 2005 FY | 6.62 Million USD | 15.35% |
| 2005 Q4 | 1.36 Million USD | -36.41% |
| 2004 Q4 | 1.74 Million USD | -0.51% |
| 2004 Q1 | 839 Thousand USD | -70.64% |
| 2004 Q2 | 1.4 Million USD | 66.87% |
| 2004 Q3 | 1.75 Million USD | 25.43% |
| 2004 FY | 5.74 Million USD | -40.62% |
| 2003 Q3 | 2.38 Million USD | 8.12% |
| 2003 Q4 | 2.85 Million USD | 19.87% |
| 2003 Q1 | 2.22 Million USD | 39.72% |
| 2003 FY | 9.66 Million USD | 49.71% |
| 2003 Q2 | 2.2 Million USD | -0.77% |
| 2002 FY | 6.45 Million USD | 196.22% |
| 2002 Q2 | 1.64 Million USD | 5.87% |
| 2002 Q3 | 1.68 Million USD | 2.44% |
| 2002 Q1 | 1.54 Million USD | 202.13% |
| 2002 Q4 | 1.59 Million USD | -5.34% |
| 2001 FY | 2.18 Million USD | -66.47% |
| 2001 Q4 | -1.51 Million USD | -209.35% |
| 2001 Q3 | 1.38 Million USD | 20.71% |
| 2001 Q2 | 1.14 Million USD | -0.95% |
| 2001 Q1 | 1.16 Million USD | -31.68% |
| 2000 Q2 | 1.57 Million USD | 4.11% |
| 2000 Q1 | 1.5 Million USD | 2.98% |
| 2000 Q3 | 1.72 Million USD | 9.87% |
| 2000 FY | 6.5 Million USD | 25.89% |
| 2000 Q4 | 1.69 Million USD | -1.62% |
| 1999 Q2 | 1.2 Million USD | 0.0% |
| 1999 Q4 | 1.46 Million USD | 4.67% |
| 1999 FY | 5.16 Million USD | 78.12% |
| 1999 Q1 | 1.2 Million USD | 20.0% |
| 1999 Q3 | 1.4 Million USD | 16.67% |
| 1998 Q2 | 500 Thousand USD | -90.91% |
| 1998 FY | 2.9 Million USD | 480.0% |
| 1998 Q3 | 700 Thousand USD | 40.0% |
| 1998 Q1 | 5.5 Million USD | 147.01% |
| 1998 Q4 | 1 Million USD | 42.86% |
| 1997 Q2 | 4.1 Million USD | 32.26% |
| 1997 Q3 | 5 Million USD | 21.95% |
| 1997 FY | 500 Thousand USD | 171.43% |
| 1997 Q4 | -11.7 Million USD | -334.0% |
| 1997 Q1 | 3.1 Million USD | 155.36% |
| 1996 Q1 | 1.5 Million USD | 116.3% |
| 1996 Q4 | -5.6 Million USD | -394.74% |
| 1996 Q3 | 1.9 Million USD | 26.67% |
| 1996 FY | -700 Thousand USD | 61.11% |
| 1996 Q2 | 1.5 Million USD | 0.0% |
| 1995 Q2 | 2.4 Million USD | -4.0% |
| 1995 Q3 | 2.5 Million USD | 4.17% |
| 1995 FY | -1.8 Million USD | 33.33% |
| 1995 Q4 | -9.2 Million USD | -468.0% |
| 1995 Q1 | 2.5 Million USD | 0.0% |
| 1994 Q3 | 1.7 Million USD | 0.0% |
| 1994 FY | -2.7 Million USD | 35.71% |
| 1994 Q2 | 1.7 Million USD | 128.33% |
| 1994 Q1 | -6 Million USD | -1100.0% |
| 1993 Q4 | 600 Thousand USD | 0.0% |
| 1993 Q2 | 600 Thousand USD | 0.0% |
| 1993 FY | -4.2 Million USD | 0.0% |
| 1993 Q3 | 600 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 72.221% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -146.912% |
| Aspira Women's Health Inc. | -18.85 Million USD | -43.46% |
| Biodesix, Inc. | -41.34 Million USD | 34.582% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -942.764% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -239.198% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -239.198% |
| Bionano Genomics, Inc. | -215.24 Million USD | 87.435% |
| CareDx, Inc | -101.9 Million USD | 73.459% |
| Check-Cap Ltd. | -19.28 Million USD | -40.224% |
| Castle Biosciences, Inc. | -67.97 Million USD | 60.214% |
| DarioHealth Corp. | -56.18 Million USD | 51.868% |
| Exact Sciences Corporation | -215.01 Million USD | 87.422% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 62.797% |
| Guardant Health, Inc. | -564.72 Million USD | 95.211% |
| ICON Public Limited Company | 956.15 Million USD | 102.829% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 102.465% |
| Illumina, Inc. | -1.06 Billion USD | 97.47% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -163.002% |
| iSpecimen Inc. | -11.16 Million USD | -142.136% |
| Standard BioTools Inc. | -76.6 Million USD | 64.693% |
| MDxHealth SA | -27.32 Million USD | 1.032% |
| 23andMe Holding Co. | -321.35 Million USD | 91.584% |
| Medpace Holdings, Inc. | 336.82 Million USD | 108.029% |
| Myriad Genetics, Inc. | -123.7 Million USD | 78.137% |
| Mainz Biomed B.V. | -26.64 Million USD | -1.502% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -157.064% |
| NeoGenomics, Inc. | -107.73 Million USD | 74.897% |
| Neogen Corporation | 58.66 Million USD | 146.102% |
| Inotiv, Inc. | -81.46 Million USD | 66.8% |
| Natera, Inc. | -446.24 Million USD | 93.939% |
| OpGen, Inc. | -15.68 Million USD | -72.388% |
| OPKO Health, Inc. | -157.02 Million USD | 82.776% |
| Psychemedics Corporation | -2.92 Million USD | -825.882% |
| Prenetics Global Limited | -52.51 Million USD | 48.499% |
| Prenetics Global Limited | -52.51 Million USD | 48.499% |
| Precipio, Inc. | -7.62 Million USD | -254.921% |
| Personalis, Inc. | -109.93 Million USD | 75.399% |
| RadNet, Inc. | 98.69 Million USD | 127.402% |
| Sera Prognostics, Inc. | -39.82 Million USD | 32.084% |
| Sotera Health Company | 276.69 Million USD | 109.774% |
| Neuronetics, Inc. | -30.55 Million USD | 11.485% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -522.296% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -522.296% |
| T2 Biosystems, Inc. | -49.66 Million USD | 45.544% |
| Twist Bioscience Corporation | -220.83 Million USD | 87.753% |
| Exagen Inc. | -22.83 Million USD | -18.426% |